Exceptions Seen in Immunohistochemistry of Rare Malignancy
Exceptions Seen in Immunohistochemistry of Rare Malignancy
S Boschert
20081013
2008 Nov 13
Elsevier Global Medical News
Exceptions Seen in Immunohistochemistry of Rare Malignancy
Elsevier Global Medical News. 2008 Nov 13, S Boschert
SAN FRANCISCO (EGMN) - The diagnosis of blastic natural killer-cell lymphoma requires a dermatopathologist who knows the typical immunohistochemical patterns of the disease and who also is aware of exceptions to rules.Also called CD4-positive, CD56-positive (CD4+/CD56+) hematodermic neoplasm, the disease is a rare, aggressive malignancy that frequently presents with skin lesions. Subjecting punch biopsy specimens to a battery of immunohistochemical stains typically produces immunopositivity for CD4,...
Advisory and Editorial Boards
Meet OncologySTAT's Advisory and Editorial Boards that represent community practitioners and academic specialists with cross-disciplinary expertise.Editors' Choice
FDA has not yet made a firm decision on whether to require KRAS testing prior to EGFR therapy for CRC despite abundant data supporting such testing.
